Julio Alvarenga Thiebaud, MD
Hematology & Oncology · Dallas, TXNPI 1457770497
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $28,807 of the $33,244 with a category attached, or 86.7%. 14 manufacturers reported payments, led by Gamida Cell Inc. at 38.3% of the total. 2025 is the largest year on record at $23,807, more than ten times the $21 reported in 2021.
Across 34 payments — averaging $977.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gamida Cell Inc.$13K
- Sanofi$9K
- Incyte Corporation$6K
- Stemline Therapeutics Inc.$5K
- Bristol Myers Squibb$500
- Jazz Pharmaceuticals Inc.$168
- plus $612 from 8 others
Across 12 payments — averaging $8812.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Deciphera Pharmaceuticals Inc.$40K
- Bristol Myers Squibb$35K
- Gilead$31K
What the payments were for
- Consulting fees$28,80787%
- Speaking & faculty fees$5002%
- Travel & lodging$2,0596%
- Food & beverage$1,8776%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gamida Cell Inc. | 3 | $12,733 |
| Sanofi | 5 | $8,652 |
| Incyte Corporation | 7 | $5,966 |
| Stemline Therapeutics Inc. | 7 | $4,612 |
| Bristol Myers Squibb | 1 | $500 |
| Jazz Pharmaceuticals Inc. | 2 | $168 |
| Sanofi-aventis U.S. LLC | 1 | $115 |
| Adaptive Biotechnologies Corporation | 1 | $103 |
| Gilead | 1 | $100 |
| Tempus AI, Inc | 1 | $96 |
| AbbVie | 2 | $86 |
| Janssen Scientific Affairs, LLC | 1 | $58 |
| Regeneron | 1 | $37 |
| GSK | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,244 in reported general payments places this provider in the 85th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SprycelDasatinib | 14 | $109,944 |
| Posaconazole | 24 | $37,371 |
| Acyclovir | 71 | $775 |
| Tacrolimus | 13 | $564 |
| Ursodiol | 13 | $545 |
| Montelukast Sodium | 13 | $265 |
| Pantoprazole Sodium | 22 | $235 |
| Gabapentin | 13 | $165 |
| Levofloxacin | 13 | $133 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $63 |
| Lorazepam | 18 | $11 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Dallas
- Edward PearsonDallas$900K
- Christopher MaiselDallas$713K
- Ashwani AgarwalDallas$275K
- Katherine WangDallas$188K
- Houston HolmesDallas$178K
- Benjamin KitchensDallas$177K
- Farrukh AwanDallas$138K
- Dai Chu LuuDallas$90K
- Luis PineiroDallas$86K
- Joan SchillerDallas$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.